Question 1

What is Labcorp Holdings's P/E ratio?

Accepted Answer

Labcorp Holdings (LH) P/E ratio is 24.8× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month earnings (net income), using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/E ratio calculated?

Accepted Answer

P/E = Share Price ÷ Trailing Twelve-Month (TTM) Diluted EPS, or equivalently Market Capitalisation ÷ TTM Net Income. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/E ratio?

Accepted Answer

The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.

Question 4

What is a good P/E ratio for Labcorp Holdings?

Accepted Answer

There is no universal "good" P/E. As a rule of thumb, the S&P 500 has historically averaged a P/E in the mid-to-high teens; mature, slow-growth businesses commonly trade in the 10–18× range, while high-growth or asset-light companies often trade at 25–50×+. What matters is the comparison to sector peers and to the company's own historical range. For Labcorp Holdings specifically, the relevant sector benchmark is the current sector median of 24.2×.

Question 5

Is Labcorp Holdings's P/E ratio high or low?

Accepted Answer

Labcorp Holdings's P/E ratio of 24.8× is above its own 5-year average of 23.0× and above the sector median of 24.2×. That places the current reading at the 51th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Labcorp Holdings's historical P/E ratio range?

Accepted Answer

In the available daily series, Labcorp Holdings (LH) P/E ratio has ranged from a low of 7.9× in 2022 to a high of 48.7× in 2025. The 5-year average is 23.0× and the 5-year median is 23.5×.

Question 7

What was Labcorp Holdings's P/E ratio in 2025?

Accepted Answer

Labcorp Holdings (LH) P/E ratio at the end of 2025 was 23.6×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month earnings figure available at that date.

Question 8

Why does Labcorp Holdings's P/E ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (earnings). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$20.7B	$877M	23.6×	-2.1×	Dec 31, 2025
2024	$19.2B	$746M	25.7×	-20.5×	Dec 31, 2024
2023	$19.3B	$418M	46.2×	+32.2×	Dec 31, 2023
2022	$17.9B	$1.28B	14.0×	+3.2×	Dec 31, 2022
2021	$25.7B	$2.38B	10.8×	-0.1×	Dec 31, 2021
2020	$17B	$1.56B	11.0×	-6.2×	Dec 31, 2020
2019	$14.1B	$824M	17.1×	+5.8×	Dec 31, 2019
2018	$10.9B	$956M	11.4×	+0.3×	Dec 31, 2018
2017	$14B	$1.27B	11.0×	-4.7×	Dec 31, 2017
2016	$11.4B	$722M	15.8×	-8.9×	Dec 31, 2016
2015	$10.8B	$436M	24.7×	+9.3×	Dec 31, 2015
2014	$7.84B	$511M	15.3×	+3.6×	Dec 31, 2014
2013	$6.73B	$574M	11.7×	-0.2×	Dec 31, 2013
2012	$6.96B	$583M	11.9×	-1.9×	Dec 31, 2012
2011	$7.17B	$520M	13.8×	+0.2×	Dec 31, 2011
2010	$7.57B	$558M	13.6×	+1.1×	Dec 31, 2010
2009	$6.79B	$546M	12.4×	-0.4×	Dec 31, 2009
2008	$5.95B	$465M	12.8×	-2.6×	Dec 31, 2008
2007	$7.35B	$477M	15.4×	-2.4×	Dec 31, 2007
2006	$7.7B	$432M	17.9×	+2.2×	Dec 31, 2006
2005	$6.06B	$386M	15.7×	-0.6×	Dec 31, 2005
2004	$5.92B	$363M	16.3×	+2.4×	Dec 31, 2004
2003	$4.47B	$321M	13.9×	+2.6×	Dec 31, 2003
2002	$2.89B	$255M	11.4×	—	Dec 31, 2002


Medtronic (MDT)	22.2×
McKesson (MCK)	22.2×
Illumina (ILMN)	21.7×
ResMed (RMD)	21.6×
GE HealthCare (GEHC)	21.6×
Pfizer (PFE)	21.1×
Quest Diagnostics (DGX)	21.1×
Henry Schein (HSIC)	21.0×
AptarGroup (ATR)	20.9×
IQVIA (IQV)	20.7×
Biogen (BIIB)	19.7×
Zoetis (ZTS)	18.9×
Gilead Sciences (GILD)	18.8×
Humana (HUM)	18.5×
Regeneron Pharmaceuticals (REGN)	18.2×
Bristol-Myers Squibb (BMY)	17.0×
Elevance Health (ELV)	17.0×
HCA Healthcare (HCA)	15.8×
AstraZeneca (AZN)	14.7×
DaVita (DVA)	13.3×
Incyte (INCY)	13.1×
Cigna (CI)	11.1×
Novo Nordisk (NVO)	8.6×
Solventum (SOLV)	7.9×
Universal Health Services (UHS)	7.2×

P/E Ratio for Labcorp Holdings (LH) 2002-2026

P/E Ratio daily chart for Labcorp Holdings (LH)

Historical P/E Ratio for Labcorp Holdings (LH) from 2002 to 2025

About P/E Ratio at Labcorp Holdings (LH)

Labcorp Holdings P/E Ratio by Year

Labcorp Holdings P/E Ratio 2025: 23.6×

Labcorp Holdings P/E Ratio 2024: 25.7×

Labcorp Holdings P/E Ratio 2023: 46.2×

Labcorp Holdings P/E Ratio 2022: 14.0×

Labcorp Holdings P/E Ratio 2021: 10.8×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

Labcorp Holdings (LH) Key Financials